Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Jr., M. Piccart (2010)
Simultaneous targeting of estrogen receptor and HER2 in breast cancerExpert Review of Anticancer Therapy, 10
H. Chuang, N. Kapuriya, S. Kulp, Ching Chen, C. Shapiro (2012)
Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cellsBreast Cancer Research and Treatment, 134
G. Freedman, P. Anderson, Tianyu Li, N. Nicolaou (2009)
Locoregional recurrence of triple‐negative breast cancer after breast‐conserving surgery and radiationCancer, 115
Xiao-Jun Ma, R. Salunga, S. Dahiya, Wilson Wang, E. Carney, V. Durbecq, A. Harris, P. Goss, C. Sotiriou, M. Erlander, D. Sgroi (2008)
A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast CancerClinical Cancer Research, 14
Bhawna Sirohi, M. Arnedos, S. Popat, Stanley Ashley, A. Nerurkar, G. Walsh, S.R.D. Johnston, I. Smith (2008)
Platinum-based chemotherapy in triple-negative breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 19 11
J. Panoff, J. Hurley, C. Takita, I. Reis, W. Zhao, V. Sujoy, C. Gomez, M. Jordá, L. Koniaris, J. Wright (2011)
Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiationBreast Cancer Research and Treatment, 128
http
//www.nccn.org/professionals/physician_gls/f_guidelines.asp
M. Kriege, C. Seynaeve, H. Meijers-Heijboer, J. Collée, M. Menke-Pluymers, C. Bartels, M. Tilanus-Linthorst, J. Blom, E. Huijskens, A. Jager, A. Ouweland, B. Geel, M. Hooning, C. Brekelmans, J. Klijn (2009)
Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 23
J. Cuzick, M. Dowsett, S. Pineda, C. Wale, J. Salter, E. Quinn, L. Zabaglo, E. Mallon, A. Green, I. Ellis, A. Howell, A. Buzdar, J. Forbes (2011)
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 32
S. Mook, M. Schmidt, B. Weigelt, B. Kreike, I. Eekhout, M. Vijver, A. Glas, A. Floore, E. Rutgers, L. Veer (2010)
The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age.Annals of oncology : official journal of the European Society for Medical Oncology, 21 4
Kyung-Il Park, Juree Kim, Sung-Nam Lim, Sehwan Han (2003)
Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy.European journal of cancer, 39 5
N. Masuda, Soo-Jung Lee, S. Ohtani, Y. Im, Eun-Sook Lee, I. Yokota, K. Kuroi, S. Im, Byeong-Woo Park, Sung-Bae Kim, Y. Yanagita, S. Ohno, S. Takao, K. Aogi, H. Iwata, Joon Jeong, Aeree Kim, K. Park, H. Sasano, Y. Ohashi, M. Toi (2017)
Adjuvant Capecitabine for Breast Cancer after Preoperative ChemotherapyThe New England Journal of Medicine, 376
P. Jézéquel, D. Loussouarn, C. Guérin-Charbonnel, L. Campion, A. Vanier, W. Gouraud, H. Lasla, C. Guette, I. Valo, V. Verrièle, M. Campone (2015)
Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune responseBreast Cancer Research : BCR, 17
S. Tolaney, Y. Boucher, D. Duda, John Martin, G. Seano, M. Ancukiewicz, W. Barry, S. Goel, Johanna Lahdenrata, S. Isakoff, E. Yeh, Saloni Jain, M. Golshan, J. Brock, M. Snuderl, E. Winer, I. Krop, R. Jain (2015)
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patientsProceedings of the National Academy of Sciences, 112
K. Voduc, Maggie Cheang, S. Tyldesley, K. Gelmon, Torsten Nielsen, H. Kennecke (2010)
Breast cancer subtypes and the risk of local and regional relapse.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 10
W. Halsted (1907)
I. The Results of Radical Operations for the Cure of Carcinoma of the Breast.Annals of surgery, 46 1
P. Cortazar, Lijun Zhang, M. Untch, K. Mehta, J. Costantino, N. Wolmark, H. Bonnefoi, D. Cameron, L. Gianni, P. Valagussa, S. Swain, Tatiana Prowell, S. Loibl, L. Wickerham, J. Bogaerts, J. Baselga, C. Perou, G. Blumenthal, J. Blohmer, E. Mamounas, J. Bergh, V. Semiglazov, R. Justice, H. Eidtmann, S. Paik, M. Piccart, R. Sridhara, P. Fasching, L. Slaets, Shenghui Tang, B. Gerber, C. Geyer, R. Pazdur, N. Ditsch, P. Rastogi, W. Eiermann, G. Minckwitz (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 384
H. Bear, G. Tang, P. Rastogi, C. Geyer, A. Robidoux, J. Atkins, Luis Baez-Diaz, A. Brufsky, R. Mehta, L. Fehrenbacher, J. Young, F. Senecal, R. Gaur, R. Margolese, P. Adams, H. Gross, J. Costantino, S. Swain, E. Mamounas, N. Wolmark (2012)
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.The New England journal of medicine, 366 4
Jiafeng Shou, Zhigang Zhang, Yucheng Lai, Zhigang Chen, Jian Huang (2016)
Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysisBMC Cancer, 16
E. Latta, E. Latta, S. Tjan, R. Parkes, F. O'Malley, F. O'Malley (2002)
The Role of HER2/neu Overexpression/Amplification in the Progression of Ductal Carcinoma In Situ to Invasive Carcinoma of the BreastModern Pathology, 15
Adjuvant! Online program www.adjuvantonline.com.
C. Palmieri, S. Saji, H. Sakaguchi, G. Cheng, A. Sunters, M. O'hare, M. Warner, Jan-Ake Gustafsson, R. Coombes, Eric Lam (2004)
The expression of oestrogen receptor (ER)-beta and its variants, but not ERalpha, in adult human mammary fibroblasts.Journal of molecular endocrinology, 33 1
C. Desmedt, A. Leo, E. Azambuja, D. Larsimont, B. Haibe-Kains, J. Selleslags, S. Delaloge, C. Duhem, J. Kains, B. Carly, M. Maerevoet, A. Vindevoghel, G. Rouas, F. Lallemand, V. Durbecq, F. Cardoso, R. Salgado, R. Rovere, Gianluca Bontempi, S. Michiels, M. Buyse, J. Nogaret, Y. Qi, F. Symmans, L. Pusztai, V. D'Hondt, M. Piccart-Gebhart, C. Sotiriou (2011)
Multifactorial approach to predicting resistance to anthracyclines.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 12
Thomas ES Rugo HS (2007)
Dec 1 (Vol
H. Alsaab, S. Sau, R. Alzhrani, K. Tatiparti, K. Bhise, S. Kashaw, A. Iyer (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical OutcomeFrontiers in Pharmacology, 8
S. Rausei, F. Rovera, G. Dionigi, Deborah Tornese, A. Fachinetti, L. Boni, R. Dionigi (2010)
Predictors of Loco‐Regional Recurrence and Cancer‐Related Death after Breast Cancer SurgeryThe Breast Journal, 16
Paula Ryan, N. Tung, S. Isakoff, Mehra Golshan, Andrea Richardson, A. Corben, Barbara Smith, R. Gelman, E. Winer, Judy Garber (2016)
Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
Gonzalez-Angulo AM Albert JM (2010)
Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a
F. André, L. Pusztai (2006)
Molecular classification of breast cancer: implications for selection of adjuvant chemotherapyNature Clinical Practice Oncology, 3
D. Slamon, W. Eiermann, N. Robert, J. Giermek, M. Martín, M. Jasiówka, J. Mackey, A. Chan, M. Liu, T. Pintér, V. Valero, C. Falkson, T. Fornander, T. Shiftan, S. Bensfia, S. Hitier, N. Xu, V. Bee-Munteanu, P. Drevot, M. Press, J. Crown (2016)
Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancerCancer Research, 76
M. Roberti, J. Arriaga, M. Bianchini, H. Quintá, A. Bravo, E. Levy, J. Mordoh, M. Barrio (2012)
Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude miceCancer Biology & Therapy, 13
Susanna Antoniotti, P. Maggiora, C. Dati, M. Bortoli (1992)
Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro.European journal of cancer, 28 2-3
P. Wirapati, C. Sotiriou, Susanne Kunkel, P. Farmer, S. Pradervand, B. Haibe-Kains, C. Desmedt, M. Ignatiadis, T. Sengstag, F. Schütz, D. Goldstein, M. Piccart, M. Delorenzi (2008)
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signaturesBreast Cancer Research : BCR, 10
L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. Somerfield, D. Hayes, R. Bast (2007)
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 33
S. Cheng, C. Horng, M. West, Erich Huang, J. Pittman, M. Tsou, H. Dressman, C. Chen, S. Tsai, J. Jian, Mei-Chin Liu, J. Nevins, A. Huang (2006)
Genomic prediction of locoregional recurrence after mastectomy in breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 28
G. Acs, N. Esposito, J. Kiluk, L. Loftus, C. Laronga (2012)
A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomasModern Pathology, 25
A. Gennari, M. Sormani, P. Pronzato, M. Puntoni, M. Colozza, Ulrich Pfeffer, P. Bruzzi (2008)
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.Journal of the National Cancer Institute, 100 1
C. Lawton (2012)
Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical TrialYearbook of Medicine, 2012
A. Wolff, M. Hammond, D. Hicks, M. Dowsett, L. McShane, K. Allison, D. Allred, J. Bartlett, M. Bilous, P. Fitzgibbons, W. Hanna, Robert Jenkins, P. Mangu, S. Paik, E. Perez, M. Press, P. Spears, G. Vance, G. Viale, D. Hayes (2013)
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 31
Eiermann W Slamon DJ (2015)
San Antonio Breast Cancer Symposium
E. Millar, P. Graham, S. O'toole, C. McNeil, L. Browne, A. Morey, Sarah Eggleton, J. Beretov, C. Theocharous, A. Capp, E. Nasser, J. Kearsley, G. Delaney, G. Papadatos, C. Fox, R. Sutherland (2009)
Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 28
Kristine Astvatsaturyan, Y. Yue, A. Walts, S. Bose (2018)
Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive featuresPLoS ONE, 13
Cheng Lu, David Romo-Bucheli, Xiangxue Wang, A. Janowczyk, S. Ganesan, Hannah Gilmore, D. Rimm, A. Madabhushi (2018)
Nuclear shape and orientation features from H&E images predict survival in early-stage estrogen receptor-positive breast cancersLaboratory Investigation, 98
Wood WC Goldhirsch A (2011)
highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol2011;22:1736–1747.
B. Weigelt, A. Mackay, R. A’Hern, R. Natrajan, D. Tan, M. Dowsett, A. Ashworth, J. Reis-Filho (2010)
Breast cancer molecular profiling with single sample predictors: a retrospective analysis.The Lancet. Oncology, 11 4
B Yeo (2015)
10.1038/bjc.2015.222.EpubBr J Cancer, 26;113
Xiao-song Chen, Ying Yuan, D. Garfield, Jiayi Wu, O. Huang, K. Shen (2014)
Both Carboplatin and Bevacizumab Improve Pathological Complete Remission Rate in Neoadjuvant Treatment of Triple Negative Breast Cancer: A Meta-AnalysisPLoS ONE, 9
Y. Ibrahim, Celina García‐García, V. Serra, Lei He, Kristine Torres-Lockhart, A. Prat, P. Antón, P. Cozar, M. Guzman, J. Grueso, Olga Rodríguez, M. Calvo, C. Aura, O. Díez, I. Rubio, J. Pérez, J. Rodón, J. Cortés, L. Ellisen, M. Scaltriti, J. Baselga (2012)
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.Cancer discovery, 2 11
E. Hahnen, B. Lederer, J. Hauke, S. Loibl, S. Kröber, A. Schneeweiss, C. Denkert, P. Fasching, J. Blohmer, C. Jackisch, S. Paepke, B. Gerber, S. Kümmel, C. Schem, G. Neidhardt, J. Huober, K. Rhiem, S. Costa, J. Altmüller, C. Hanusch, H. Thiele, V. Müller, P. Nürnberg, T. Karn, V. Nekljudova, M. Untch, G. Minckwitz, R. Schmutzler (2017)
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical TrialJAMA Oncology, 3
F. André, C. Hatzis, K. Anderson, C. Sotiriou, C. Mazouni, J. Mejia, Bailiang Wang, G. Hortobagyi, W. Symmans, L. Pusztai (2007)
Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor–Positive Breast CancerClinical Cancer Research, 13
(2018)
Abstract number 90, presented at UAE Cancer Congress
B. Yeo, L. Zabaglo, M. Hills, A. Dodson, I. Smith, M. Dowsett (2015)
Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact studyBritish Journal of Cancer, 113
J. Warren, C. Klabunde, D. Schrag, P. Bach, G. Riley (2002)
Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly PopulationMedical Care, 40
Xuan Li, Danian Dai, Bo Chen, Hailin Tang, Xiaoming Xie, Weidong Wei (2018)
Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 PatientsDisease Markers, 2018
B. Kaufman, J. Mackey, M. Clemens, P. Bapsy, A. Vaid, A. Wardley, S. Tjulandin, M. Jahn, M. Lehle, A. Feyereislova, C. Révil, A. Jones (2009)
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 33
M. Kyndi, F. Sørensen, H. Knudsen, M. Overgaard, H. Nielsen, J. Overgaard (2008)
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 9
S. Paik, G. Tang, S. Shak, Chungyeul Kim, J. Baker, W. Kim, M. Cronin, F. Baehner, D. Watson, J. Bryant, J. Costantino, C. Geyer, D. Wickerham, N. Wolmark (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 23
A. Lipton, S. Ali, K. Leitzel, Laurence Demers, Vernon Chinchilli, L. Engle, H. Harvey, C. Brady, C. Nalin, M. Dugan, W. Carney, Jeffrey Allard (2002)
Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 6
B. Abdulkarim, J. Cuartero, J. Hanson, J. Deschênes, D. Lesniak, S. Sabri (2011)
Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 21
R. Rouzier, Radhika Rajan, P. Wagner, K. Hess, D. Gold, J. Stec, M. Ayers, M. Ayers, J. Ross, J. Ross, Peter Zhang, T. Buchholz, H. Kuerer, Marjorie Green, B. Arun, G. Hortobagyi, W. Symmans, L. Pusztai, L. Pusztai (2005)
Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.Proceedings of the National Academy of Sciences of the United States of America, 102 23
T. Byrski, J. Gronwald, T. Huzarski, E. Grzybowska, M. Budryk, M. Stawicka, T. Mierzwa, M. Szwiec, R. Wiśniowski, M. Siołek, R. Dent, J. Lubiński, S. Narod (2010)
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 3
D. Silver, A. Richardson, A. Eklund, Z. Wang, Z. Szallasi, Qiyuan Li, N. Juul, C. Leong, Diana Calogrias, Ayodele Buraimoh, Aquila Fatima, R. Gelman, P. Ryan, N. Tung, A. Nicolo, S. Ganesan, A. Miron, C. Colín, D. Sgroi, L. Ellisen, E. Winer, J. Garber (2010)
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 7
L. Lousberg, J. Collignon, G. Jerusalem (2016)
Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategiesTherapeutic Advances in Medical Oncology, 8
L. Mcghan, A. McCullough, C. Protheroe, A. Dueck, James Lee, R. Núñez-Nateras, E. Castle, R. Gray, N. Wasif, M. Goetz, J. Hawse, T. Henry, M. Barrett, H. Cunliffe, B. Pockaj (2014)
Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer SubtypeAnnals of Surgical Oncology, 21
G. Landskron, M. Fuente, P. Thuwajit, C. Thuwajit, M. Hermoso (2014)
Chronic Inflammation and Cytokines in the Tumor MicroenvironmentJournal of Immunology Research, 2014
M. Dowsett (2001)
Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer.Endocrine-related cancer, 8 3
C. Horak, Francis Lee, Li-An Xu, S. Galbraith, J. Baselga (2016)
High β-III tubulin expression in triple-negative (TN) breast cancer (BC) subtype and correlation to ixabepilone response: A retrospective analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
(2008)
BMC Genomics BioMed Central
S. Greenberg, H. Rugo (2010)
Triple-Negative Breast Cancer: Role of Antiangiogenic AgentsThe Cancer Journal, 16
(2007)
Combination therapy with the novel epothilone B analog , ixabepilone , plus capecitabine has efficacy in ER / PR / HER 2 - negative breast cancer resistant to anthracyclines and taxanes
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
Jenny Chang, Eric Wooten, A. Tsimelzon, S. Hilsenbeck, M. Gutiérrez, R. Elledge, S. Mohsin, C. Osborne, G. Chamness, D. Allred, P. O’Connell (2003)
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancerThe Lancet, 362
J. Sparano, R. Gray, D. Makower, K. Pritchard, K. Albain, D. Hayes, C. Geyer, E. Dees, M. Goetz, J. Olson, T. Lively, S. Badve, T. Saphner, L. Wagner, T. Whelan, M. Ellis, S. Paik, W. Wood, P. Ravdin, M. Keane, H. Moreno, P. Reddy, T. Goggins, I. Mayer, A. Brufsky, D. Toppmeyer, V. Kaklamani, J. Berenberg, J. Abrams, G. Sledge (2018)
Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast CancerThe New England Journal of Medicine, 379
M. Buyse, S. Loi, L. Veer, G. Viale, M. Delorenzi, A. Glas, M. D'assignies, J. Bergh, R. Lidereau, P. Ellis, A. Harris, J. Bogaerts, P. Therasse, A. Floore, M. Amakrane, F. Piette, E. Rutgers, C. Sotiriou, F. Cardoso, M. Piccart (2006)
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.Journal of the National Cancer Institute, 98 17
M. Vijver, Yudong He, L. Veer, H. Dai, A. Hart, D. Voskuil, G. Schreiber, J. Peterse, C. Roberts, M. Marton, M. Parrish, D. Atsma, A. Witteveen, A. Glas, L. Delahaye, Tony Velde, H. Bartelink, S. Rodenhuis, E. Rutgers, S. Friend, René Bernards (2002)
A gene-expression signature as a predictor of survival in breast cancer.The New England journal of medicine, 347 25
S Mook (2009)
10.1007/s10549-008-0130-2Breast Cancer Res Treat, 116
L. Gianni, W. Eiermann, V. Semiglazov, A. Lluch, S. Tjulandin, M. Zambetti, A. Moliterni, F. Vázquez, M. Byakhov, M. Lichinitser, M. Climent, E. Ciruelos, B. Ojeda, M. Mansutti, A. Bozhok, D. Magazzù, D. Heinzmann, J. Steinseifer, P. Valagussa, J. Baselga (2014)
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.The Lancet. Oncology, 15 6
J. Albert, A. González-Angulo, M. Guray, A. Sahin, E. Strom, W. Tereffe, W. Woodward, S. Tucker, K. Hunt, G. Hortobagyi, T. Buchholz (2009)
Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer.International journal of radiation oncology, biology, physics, 77 5
E. Arriola, S. Rodríguez-Pinilla, M. Lambros, Robin Jones, Michelle James, K. Savage, I. Smith, M. Dowsett, J. Reis-Filho (2007)
Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancerBreast Cancer Research and Treatment, 106
M. Laurentiis, G. Arpino, E. Massarelli, A. Ruggiero, C. Carlomagno, F. Ciardiello, G. Tortora, D. D'Agostino, F. Caputo, G. Cancello, E. Montagna, L. Malorni, L. Zinno, R. Lauria, A. Bianco, S. Placido (2005)
A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast CancerClinical Cancer Research, 11
ME Hammond (2010)
10.5858/134.6.907Arch Pathol Lab Med, 134
A. Giuliano, K. Hunt, K. Ballman, P. Beitsch, P. Whitworth, P. Blumencranz, A. Leitch, S. Saha, L. Mccall, M. Morrow (2011)
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.JAMA, 305 6
C. Leong, N. Vidnovic, M. DeYoung, D. Sgroi, L. Ellisen (2007)
The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers.The Journal of clinical investigation, 117 5
L. Gianni, M. Zambetti, K. Clark, J. Baker, M. Cronin, J. Wu, G. Mariani, Jaime Rodriguez, M. Carcangiu, D. Watson, P. Valagussa, R. Rouzier, W. Symmans, J. Ross, G. Hortobagyi, L. Pusztai, S. Shak (2004)
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 29
A. Leo, D. Gancberg, D. Larsimont, M. Tanner, T. Jarvinen, G. Rouas, S. Dolci, J. Leroy, M. Paesmans, J. Isola, M. Piccart (2002)
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 5
Means-Powell J Mayer I
Mayer I, Means-Powell J, Shyr Y, Arteaga C. A phase Ib trial of erlotinib, an EGFR inhibitor, and everolimus (RAD001), an mTOR inhibitor, in patients with metastatic breast cancer.
Shin-Ae Kang, Jye Guan, H. Tan, Tinghine Chu, A. Thike, C. Bernadó, J. Arribas, C. Wong, P. Tan, M. Gudi, T. Putti, J. Sohn, S. Lim, S. Lee, Y. Lim (2018)
Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric StudyClinical Cancer Research, 25
M. Hammond, Daniel Hayes, M. Dowsett, D. Allred, K. Hagerty, S. Badve, P. Fitzgibbons, G. Francis, Neil Goldstein, M. Hayes, David Hicks, S. Lester, R. Love, P. Mangu, L. McShane, K. Miller, C. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, Jared Schwartz, Fred Sweep, S. Taube, E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R. Williams, J. Wittliff, Antonio Wolff (2010)
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 16
Ravdin Pm (1996)
A computer program to assist in making breast cancer adjuvant therapy decisions.Seminars in Oncology, 23
L. Pusztai, Jong-Hyeon Jeong, Y. Gong, J. Ross, Chungyeul Kim, S. Paik, R. Rouzier, F. André, G. Hortobagyi, N. Wolmark, W. Symmans (2009)
Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 26
B Fleisher (2016)
10.2147/BCTT.S114659Breast Cancer - Targets and Therapy, 8
C. Benz, G. Scott, J. Sarup, Randolph Johnson, D. Tripathy, E. Coronado, H. Shepard, C. Osborne (1992)
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neuBreast Cancer Research and Treatment, 24
B. Fisher (1992)
The evolution of paradigms for the management of breast cancer: a personal perspective.Cancer research, 52 9
H. Soliman, F. Khalil, S. Antonia (2014)
PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer CellsPLoS ONE, 9
C. Minami, D. Chung, Helena Chang (2011)
Management Options in Triple-Negative Breast CancerBreast Cancer : Basic and Clinical Research, 5
A. Knoop, H. Knudsen, E. Balslev, B. Rasmussen, J. Overgaard, K. Nielsen, A. Schonau, K. Gunnarsdóttir, K. Olsen, H. Mouridsen, B. Ejlertsen (2005)
retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 30
M. Filipits, M. Rudas, R. Jakesz, P. Dubsky, F. Fitzal, C. Singer, O. Dietze, R. Greil, Andrea Jelen, P. Sevelda, C. Freibauer, V. Müller, F. Jänicke, Marcus Schmidt, H. Kölbl, A. Rody, M. Kaufmann, W. Schroth, H. Brauch, M. Schwab, P. Fritz, K. Weber, I. Feder, G. Hennig, R. Kronenwett, M. Gehrmann, M. Gnant (2011)
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk FactorsClinical Cancer Research, 17
R. García-Becerra, N. Santos, L. Díaz, J. Camacho (2012)
Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based ResistanceInternational Journal of Molecular Sciences, 14
Frances O'Malley, Stephen Chia, Dongsheng Tu, Lois Shepherd, Mark Levine, Vivien Bramwell, I. Andrulis, K. Pritchard (2009)
Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.Journal of the National Cancer Institute, 101 9
A. Sonnenblick, E. Azambuja, H. Azim, M. Piccart (2015)
An update on PARP inhibitors—moving to the adjuvant settingNature Reviews Clinical Oncology, 12
W. Mondesire, W. Jian, Haixia Zhang, J. Ensor, M. Hung, G. Mills, F. Meric-Bernstam (2004)
Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer CellsClinical Cancer Research, 10
P. Ravdin, L. Siminoff, G. Davis, M. Mercer, J. Hewlett, N. Gerson, H. Parker (2001)
Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 4
J. Wheler, J. Atkins, F. Janku, S. Moulder, R. Yelensky, P. Stephens, R. Kurzrock (2015)
Multiple gene aberrations and breast cancer: lessons from super-respondersBMC Cancer, 15
S. Paik, S. Shak, G. Tang, Chungyeul Kim, J. Baker, M. Cronin, F. Baehner, M. Walker, D. Watson, T. Park, W. Hiller, E. Fisher, D. Wickerham, J. Bryant, N. Wolmark, Genomic Health, Redwood City, S. Francisco (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.The New England journal of medicine, 351 27
J. Cortés, J. O’Shaughnessy, D. Loesch, J. Blum, L. Vahdat, K. Petráková, P. Chollet, A. Manikas, V. Diéras, T. Delozier, V. Vladimirov, F. Cardoso, H. Koh, P. Bougnoux, C. Dutcus, S. Seegobin, D. Mir, N. Meneses, J. Wanders, C. Twelves (2011)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 377
M. Hammond, D. Hayes, M. Dowsett, D. Allred, K. Hagerty, S. Badve, P. Fitzgibbons, G. Francis, N. Goldstein, M. Hayes, D. Hicks, S. Lester, R. Love, P. Mangu, L. McShane, K. Miller, C. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, J. Schwartz, F. Sweep, S. Taube, E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R. Williams, J. Wittliff, A. Wolff (2010)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).Archives of pathology & laboratory medicine, 134 7
M. Pistelli, M. Caramanti, T. Biscotti, A. Santinelli, A. Pagliacci, M. Lisa, Z. Ballatore, F. Ridolfi, E. Maccaroni, R. Bracci, R. Berardi, N. Battelli, S. Cascinu (2014)
Androgen Receptor Expression in Early Triple-Negative Breast Cancer: Clinical Significance and Prognostic AssociationsCancers, 6
C. Perou, T. Sørlie, M. Eisen, M. Rijn, S. Jeffrey, Christian Rees, J. Pollack, D. Ross, H. Johnsen, L. Akslen, Ø. Fluge, Alexander Pergamenschikov, Cheryl Williams, Shirley Zhu, P. Lønning, A. Børresen-Dale, P. Brown, D. Botstein (2000)
Molecular portraits of human breast tumoursNature, 406
M. Tanner, J. Isola, T. Wiklund, B. Erikstein, P. Kellokumpu-Lehtinen, P. Malmström, N. Wilking, J. Nilsson, J. Bergh (2006)
Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 16
Xiao-Jun Ma, Zuncai Wang, P. Ryan, S. Isakoff, A. Barmettler, Andrew Fuller, B. Muir, G. Mohapatra, R. Salunga, J. Tuggle, Y. Tran, D. Tran, Ana Tassin, Paul Amon, Wilson Wang, Wen Wang, E. Enright, K. Stecker, Eden Estepa-Sabal, Barbara Smith, J. Younger, U. Balis, J. Michaelson, A. Bhan, K. Habin, T. Baer, J. Brugge, D. Haber, M. Erlander, D. Sgroi (2004)
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.Cancer cell, 5 6
G. Minckwitz, Chiun-Sheng Huang, M. Mano, S. Loibl, E. Mamounas, M. Untch, N. Wolmark, P. Rastogi, A. Schneeweiss, A. Redondo, H. Fischer, W. Jacot, A. Conlin, C. Arce‐Salinas, I. Wapnir, C. Jackisch, M. DiGiovanna, P. Fasching, J. Crown, P. Wülfing, Z. Shao, E. Caremoli, Haiyan Wu, L. Lam, D. Tesarowski, M. Smitt, Hannah Douthwaite, S. Singel, C. Geyer (2019)
Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast CancerThe New England Journal of Medicine, 380
A. Jones (2003)
Combining trastuzumab (Herceptin) with hormonal therapy in breast cancer: what can be expected and why?Annals of oncology : official journal of the European Society for Medical Oncology, 14 12
K. Ratnam, J. Low (2007)
Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in OncologyClinical Cancer Research, 13
S. Johnston, J. Pippen, X. Pivot, M. Lichinitser, S. Sadeghi, V. Diéras, H. Gómez, G. Romieu, A. Manikhas, M. Kennedy, M. Press, J. Maltzman, A. Florance, L. O’Rourke, C. Oliva, S. Stein, M. Pegram (2009)
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 33
S. Shiovitz, S. Shiovitz, L. Korde, L. Korde (2015)
Genetics of breast cancer: a topic in evolution.Annals of oncology : official journal of the European Society for Medical Oncology, 26 7
Antonio Wolff, M. Hammond, David Hicks, M. Dowsett, Lisa McShane, Kimberly Allison, D. Allred, John Bartlett, M. Bilous, P. Fitzgibbons, W. Hanna, Robert Jenkins, P. Mangu, S. Paik, Edith Perez, Michael Press, Patricia Spears, Gail Vance, G. Viale, Daniel Hayes (2014)
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Archives of pathology & laboratory medicine, 138 2
A. Lænkholm, M. Jensen, J. Eriksen, B. Rasmussen, A. Knoop, Wesley Buckingham, S. Ferree, C. Schaper, T. Nielsen, T. Haffner, Torben Kibøl, Maj-Lis Talman, Anne Jylling, T. Tabor, B. Ejlertsen (2018)
PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 8
Z Hu (2006)
10.1186/1471-2164-7-96BMC Genomics, 7
A. Goldhirsch, W. Wood, A. Coates, R. Gelber, B. Thürlimann, H. Senn, Panel Members (2011)
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Annals of Oncology, 22
G. Viale, F. Snoo, L. Slaets, J. Bogaerts, L. Veer, E. Rutgers, M. Piccart-Gebhart, L. Stork-Sloots, A. Glas, L. Russo, P. Dell'Orto, K. Tryfonidis, S. Litière, Fatima Cardoso, Mindact investigators (2017)
Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trialBreast Cancer Research and Treatment, 167
Damya Laoui, K. Movahedi, Eva Overmeire, J. Bossche, E. Schouppe, C. Mommer, Alexandros Nikolaou, Yannick Morias, P. Baetselier, J. Ginderachter (2011)
Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions.The International journal of developmental biology, 55 7-9
T. Järvinen, M. Tanner, V. Rantanen, M. Bärlund, Å. Borg, S. Grénman, J. Isola (2000)
Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.The American journal of pathology, 156 3
Mackey J Slamon DJ (2007)
San Antonio
J. Parker, Michael Mullins, M. Cheang, S. Leung, D. Voduc, T. Vickery, S. Davies, C. Fauron, Xiaping He, Zhiyuan Hu, J. Quackenbush, I. Stijleman, J. Palazzo, J. Marron, A. Nobel, E. Mardis, T. Nielsen, M. Ellis, C. Perou, P. Bernard (2009)
Supervised risk predictor of breast cancer based on intrinsic subtypes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 8
Mala Pande, M. Bondy, K. Do, A. Sahin, J. Ying, G. Mills, P. Thompson, A. Brewster (2014)
Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survivalBreast Cancer Research and Treatment, 147
S. Ellard, M. Clemons, K. Gelmon, B. Norris, H. Kennecke, S. Chia, K. Pritchard, A. Eisen, T. Vandenberg, Marianne Taylor, E. Sauerbrei, M. Mishaeli, D. Huntsman, W. Walsh, M. Olivo, L. Mcintosh, L. Seymour (2009)
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 27
田村 隆行 (2011)
Annual San Antonio Breast Cancer Symposium に参加して, 67
Marjorie De la Fuente Glauben Landskron (2014)
Article ID 149185
A. Ho, G. Gupta, T. King, C. Perez, S. Patil, K. Rogers, Y. Wen, E. Brogi, M. Morrow, C. Hudis, T. Traina, B. McCormick, S. Powell, M. Robson (2012)
Favorable prognosis in patients with T1a/T1bN0 triple‐negative breast cancers treated with multimodality therapyCancer, 118
T. Sørlie, R. Tibshirani, Joel Parker, T. Hastie, J. Marron, A. Nobel, Shibing Deng, H. Johnsen, Robert Pesich, S. Geisler, J. Demeter, C. Perou, P. Lønning, P. Brown, A. Børresen-Dale, D. Botstein (2003)
Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences of the United States of America, 100
A Lipton (2002)
10.1200/JCO.2002.20.6.1467J Clin Oncol, 20
Brett Fleisher, C. Clarke, S. Ait-Oudhia
Breast Cancer -targets and Therapy Dovepress Current Advances in Biomarkers for Targeted Therapy in Triple-negative Breast Cancer
Miao Liu, Q. Mo, Changyuan Wei, Q. Qin, Zhen Huang, Jié He (2012)
Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysisOncology Letters, 5
D. Slamon, M. Press (2009)
Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers.Journal of the National Cancer Institute, 101 9
B. Lehmann, B. Jovanovic, Xi Chen, M. Estrada, Kimberly Johnson, Y. Shyr, H. Moses, M. Sanders, J. Pietenpol (2016)
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy SelectionPLoS ONE, 11
R. Pietras, M. Arboleda, Reese Dm, N. Wongvipat, Pegram, Lillian Ramos, C. Gorman, Parker Mg, M. Sliwkowski, D. Slamon (1995)
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.Oncogene, 10 12
G. Wishart, E. Azzato, D. Greenberg, J. Rashbass, O. Kearins, G. Lawrence, C. Caldas, P. Pharoah (2010)
PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancerBreast Cancer Research : BCR, 12
Abstract number (2018)
Abstract number 90, presented at UAE Cancer Congress 2018, Dubai
M. Ayers, W. Symmans, J. Stec, A. Damokosh, E. Clark, K. Hess, M. Lecocke, J. Métivier, D. Booser, N. Ibrahim, V. Valero, M. Royce, B. Arun, G. Whitman, J. Ross, N. Sneige, G. Hortobagyi, L. Pusztai (2004)
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 12
M. Dowsett, J. Cuzick, C. Wale, J. Forbes, E. Mallon, J. Salter, E. Quinn, A. Dunbier, M. Baum, A. Buzdar, A. Howell, R. Bugarini, F. Baehner, S. Shak (2010)
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 11
N. Turner, A. Tutt, A. Ashworth (2004)
Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 4
R. Santana-Davila, E. Perez (2010)
Treatment options for patients with triple-negative breast cancerJournal of Hematology & Oncology, 3
M. Donker, M. Straver, P. Meijnen, C. Velde, R. Mansel, H. Westenberg, L. Orzalesi, W. Bouma, H. Mijle, G. Nieuwenhuijzen, S. Veltkamp, L. Slaets, C. Messina, N. Duez, C. Hurkmans, J. Bogaerts, G. Tienhoven (2013)
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: Final analysis of the EORTC AMAROS trial (10981/22023).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 18_suppl
Warren Tseng, S. Martinez (2010)
Metaplastic Breast Cancer: To Radiate or Not to Radiate?Annals of Surgical Oncology, 18
P. Nguyen, A. Taghian, M. Katz, A. Niemierko, R. Raad, Whitney Boon, J. Bellon, J. Wong, Barbara Smith, J. Harris (2008)
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 14
I. Mayer, J. Means-Powell, Y. Shyr, C. Arteaga (2009)
A Phase Ib Trial of Erlotinib, an EGFR Inhibitor, and Everolimus (RAD001), an mTOR Inhibitor, in Patients with Metastatic Breast Cancer.Cancer Research, 69
J. Ioannidis, D. Allison, C. Ball, I. Coulibaly, X. Cui, A. Culhane, M. Falchi, Cesare Furlanello, L. Game, Giuseppe Jurman, J. Mangion, Tapan Mehta, Michael Nitzberg, G. Page, E. Petretto, V. Noort (2009)
Repeatability of published microarray gene expression analysesNature Genetics, 41
Breast cancer is no longer considered a single disease, and with better understanding of cancer biology, its management has evolved over the years, into a complex individualized use of therapeutics based on variable expressions of predictive and prognostic factors. With the advent of molecular and genetic research, the complexity and diversity of breast cancer cells and their ability to survive and develop resistance to treatment strategies became more evident. At the same time, targeted therapies evolved, as specific targets were discovered such as HER2 receptor, and androgen receptor. More recent is the development of immunotherapy which aims at strengthening the host immune system to identify and kill the tumor cells. In breast cancer treatment, use of molecular tests has been a target of controversies, due to their high costs and inaccessibility in limited resource situations. Research in breast cancer is also proceeding at a rapid pace, but it is important to remember that breast cancer continues to be a complex interplay of alterations at molecular and genetic level, with the variability in expressions at protein level leading to difference in behavior and responses to treatment and overall outcome. In the succeeding paragraphs, we will try to review the available evidence in literature and attempt to understand the molecular complexity of breast cancer in order to simplify the art of treating the disease and improving outcomes.
"Indian Journal of Surgical Oncology" – Springer Journals
Published: Aug 10, 2019
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.